Introduction
The recognition of cancer as a genetic disease is more than a century old and stems from observations by David von Hansemann and Theodor Boveri that cancer cells display chromosomal abnormalities (Boveri, 1914; von Hansemann, 1890) . In the early 20 th century, Francis Rous revealed that retroviruses could drive sarcoma formation in chickens (Rous, 1911) . Many decades later, in 1970, the Rous sarcoma virus was found to carry a gene called v-Src, the first oncogene to be identified (Duesberg and Vogt, 1970; Stehelin et al., 1976) . Concurrently, it was discovered that not only activation, but also inactivation of so-called tumor suppressor genes (TSGs) can lead to tumorigenesis (Knudson, 1971) . (Proto-)oncogenes and TSGs regulate essential cellular processes like cell cycle, apoptosis, migration, and survival, and genetic aberrations that lead to dysregulation or loss of function of these genes can result in malignant transformation. The generation of transgenic mice carrying an activated oncogene, also called oncomice, in the 1980s and TSG knockout mice in the 1990s further substantiated the notion that oncogene expression or loss of TSGs in normal mammalian cells leads to cancer development (Adams et al., 1985; Donehower et al., 1992; Hanahan et al., 2007; Stewart et al., 1984) . The dependency of cancers on these dysregulated genes was demonstrated in genetically engineered mouse models (GEMMs) in which de-activation of oncogenes or re-expression of TSGs in fully established tumors led to rapid tumor regression (Fisher et al., 2001; Jain et al., 2002; Moody et al., 2002; Ventura et al., 2007) . These insights into the causal role of genetic aberrations in cancer initiation and progression spurred the long-held belief that tumorigenesis is entirely driven by cancer-cell-intrinsic genetic traits. However, over the past couple of decades, this dogma has been challenged by new experimental evidence demonstrating that genetic aberrations alone are required, but not sufficient, for a cancer to develop. Like a seed needing fertile soil for successful germination, cancer cells only survive and develop into invasive tumors in an environment that provides sufficient nutrients and oxygen, and that lacks strong cytotoxic signals. In this review, we will focus on one of the most influential cancer cell-extrinsic regulators of cancer biology, the immune system. Similar to its physiological function, the immune system exerts multifaceted tasks in tumor-bearing hosts, with different immune cells playing different and sometimes opposing roles. The composition and function of immune cells in tumors differs greatly between, but also within, cancer types. For example, of the breast cancer subtypes, triple-negative breast cancer (TNBC) presents with highest levels of tumor-infiltrating lymphocytes (TIL) and macrophages (Medrek et al., 2012; Stanton et al., 2016) . Striking differences in relative leukocyte composition between different tumor types were observed in a study that integrated gene expression and clinical outcome data of over 18,000 human tumors (Gentles et al., 2015) . Moreover, this study revealed considerable variation in intratumoral presence of certain immune cell subsets and how these were associated with cancer-specific outcomes. For example, whereas memory CD4 + T cells were associated with adverse outcome in bladder cancer patients, they correlated with favorable outcome in lung adenocarcinoma patients (Gentles et al., 2015) , suggesting that differences in immune profile are not only phenotypically distinct but are also of functional consequence. But what determines this substantial variation in immune contexture between different tumors? Given the surge of interest in utilizing immunomodulatory drugs for the treatment of cancer patients, it is critical to understand the underlying tumor characteristics that dictate the inter-tumor heterogeneity in immune landscapes and to use this knowledge for rational decision-making in the clinical use of immunomodulatory strategies.
In this review, we will discuss recent insights into how cancer cell-intrinsic properties can dictate the immune landscape of tumor-bearing hosts. Specifically, we will examine which genetic aberrations correlate with immune cell composition in human tumors. Next, we will discuss the current knowledge on oncogene-and TSG-dependent signaling pathways that underlie the differential crosstalk of cancer cells with the immune system as identified in genetically engineered mouse tumor models (GEMMs). Finally, we will discuss how the growing insights into these mechanisms may open new avenues for personalized immune intervention strategies for cancer patients.
Genetic Makeup Influencing the Immune Contexture of Tumors-Observations from the Clinic
In 1863, the German pathologist Rudolf Virchow was the first to hypothesize a link between the development of tumors and the inflammatory state of their anatomical location (Balkwill and Mantovani, 2001) . Around the same time, William Coley, pioneer of cancer immunotherapy, demonstrated that some patients displayed tumor regression after being injected with immune stimulatory Streptococcus pyogenes cultures (Coley, 1893) . Nowadays, it is fully established that inflammation can be causally linked with human cancers and that the immune infiltrate of human tumors contains prognostic and predictive information (Diakos et al., 2014; Gentles et al., 2015) . Moreover, cancer immunotherapy has revolutionized cancer treatment (Yang, 2015) , illustrating that immune cells can be harnessed successfully to destroy tumors in a proportion of cancer patients. Recently, studies have started to explore the cancer cell characteristics-including the genetic makeup-that play a critical role in dictating the heterogeneity in immune landscape between different tumors. Studies aimed at assessing the link between the genetics of human tumors and the immune infiltrate can be roughly divided into three categories: (1) studies that have assessed the extent of the mutational load of tumors with T cell abundance, specificity and activity, (2) studies that have linked distinct molecular tumor subtypes with a certain immune landscape, and (3) studies that have focused on the association between defined oncogenic driver mutations or loss of TSGs and parameters of the inflammatory tumor microenvironment. In this section, we will discuss the findings of these three different strategies to assess the impact of genetic events on the crosstalk with the immune system.
The core function of the adaptive immune system is to recognize and destroy cells expressing non-self-antigens, while not responding to self-antigens. Because cancers arise from host cells, these cancer cells, with the exception of viral-associated cancers, do not express the typical immunogenic foreign antigens as seen in infections. The recent clinical breakthrough of immune checkpoint inhibitors has fueled studies aimed at identifying the tumor antigens that are recognized by effective antitumor immune responses. This resulted in the hypothesis that a higher mutational load of a tumor will inevitably result in more ''foreign'' peptide presentation and consequently higher immunogenicity of the tumor. Mutations and other genomic rearrangements in cancer cells can encode for neo-antigens, antigens uniquely expressed by the tumor, that when presented by MHC molecules can potentially be recognized by the endogenous T cell repertoire (Schumacher and Schreiber, 2015) . Indeed, neo-antigen-specific T cells have been observed in melanoma patients (Lennerz et al., 2005; Linnemann et al., 2015; Robbins et al., 2013; van Rooij et al., 2013; Wö lfel et al., 1995) and tumor types with a relatively high mutational burden, such as melanoma, non-small cell lung cancer (NSCLC) and microsatellite-instable (MSI) tumors display increased T cell influx and have an overall better response rate to immunotherapeutics compared to tumors with a lower mutational load (Le et al., 2015; Rizvi et al., 2015; Van Allen et al., 2015) . Nevertheless, there is a substantial number of patients with good response and low mutational load and vice versa (Balli et al., 2017; Charoentong et al., 2017; Hugo et al., 2016; Rizvi et al., 2015; Robinson et al., 2017; Spranger et al., 2016) . These observations suggest that for some tumors the mutational burden of tumors can serve as a quantitative measure for T cell abundance and likelihood to respond to immune checkpoint inhibitors. However, there are clearly additional determinants of the immune contexture in tumors besides mutational load.
Distinct molecular subtypes of human cancers can be associated with a defined immune composition and activation state in the tumor microenvironment. Several cancer types can be subtyped based on their molecular and genetic profile, thus forming separate classes within a given tumor type, often with distinct progression characteristics and treatment regimens. (Parker et al., 2009) . It has been reported that CD8 + T cells preferentially infiltrate in triple negative tumors and those patients with high intratumoral T cell abundance show better disease-free survival Medrek et al., 2012; Savas et al., 2016; Stanton et al., 2016) . Breast tumors that express hormone receptors or HER2 are more frequently infiltrated by FoxP3 + regulatory T cells (Tregs) compared to other subtypes, suggesting dependency on these receptors in the establishment of an immunosuppressive milieu (Decker et al., 2012; Jiang et al., 2015) . Accordingly, the presence of Tregs in breast tumors predicted metastatic progression and poor survival (Jiang et al., 2015; Liu et al., 2011) . For other cancer types, such as colorectal cancer, glioblastoma, and head and neck cancer, similar subtypespecific tumor immune infiltrates have been observed (Becht et al., 2016; Doucette et al., 2013; Keck et al., 2015; Wang et al., 2017) (Table 1) . These clinical observations indicate that different molecular subtypes of tumors can be characterized by distinct immune landscapes. However, due to the complex nature that underlies molecular subtypes, the exact genes and mechanisms that determine this immune heterogeneity cannot be distilled from these studies.
A growing body of clinical observations indicates that defined oncogenic driver mutations and loss of TSGs in human cancers are also correlated with changes in immune composition and immunotherapy response. For example, loss of NF1 in glioblastomas associated with an increase in macrophages in the tumor (Wang et al., 2017) . Another study showed that loss of heterozygosity (LOH) or mutation of TP53 in ER-negative and basal-like breast tumors is associated with decreased intratumoral expression of a cytotoxic T cell signature and poor survival (Quigley et al., 2015) . These studies indicate that a single TSG can be associated with the immune composition of the tumor, across different tumor subtypes, and therefore might be a dominant driving force of immune influx. Furthermore, in pancreatic ductal adenocarcinoma (PDAC), expression of genes associated with cytotoxic T cell function and immune checkpoint molecules was inversely linked with amplification of MYC, NOTCH2, and FGFR1, but not with mutational load (Balli et al., 2017 Balli et al., 2017) and suggests that aberrant expression of oncogenic pathways also dominantly impacts the composition of the pancreatic tumor microenvironment (Table 1) .
Genetic aberrations in tumors can also influence the T cell response by altering expression levels of immune checkpoint molecules by cancer cells. In a cohort of lung adenocarcinoma patients, accumulation of p53 in tumor cells, which is indicative of mutations in TP53, correlated with increased PD-L1 expression, while mutant EGFR tumors were characterized by low expression of PD-L1 (Cha et al., 2016) . In contrast, another study showed that EGFR mutated lung tumors have high levels of PD-L1 (Akbay et al., 2013) , demonstrating that the role of mutant EGFR in regulating PD-L1 expression is still under debate. In metastatic neuroblastoma, amplification of MYCN correlated with low expression of PD-L1 and a reduced T cell gene-expression signature in the tumor compared to MYCN-normal tumors (Layer et al., 2017) . Moreover, MYCN overexpression inversely correlated with natural killer (NK) cell-activating factors such as NKG2D in primary human neuroblastoma cell lines (Brandetti et al., 2017) . In addition, resistance to anti-PD-1 treatment in melanoma and MSI CRC patients correlated with mutations in JAK1/2 (Shin et al., 2017) . Using human melanoma cell lines, it was shown that JAK1/2 mutations led to an impaired IFN signaling pathway-mediated PD-L1 expression, suggesting that also JAK-STAT signaling is involved in regulating immune checkpoint expression. These findings indicate that screening for expression of certain oncogenes or loss of function of specific TSGs might be exploited to improve the stratification of cancer patients for therapeutic targeting the PD-1/PD-L1 axis.
The link between the genetic makeup of tumors and their immune contexture was further strengthened by recent highthroughput next generation sequencing (NGS) studies, which allow an unbiased assessment of the genetics of tumors in parallel with high-resolution mapping of the tumor immune landscape. By correlating an RNA-based metric of immune cytolytic activity (mainly associated with T and NK cell function) with genetic data from the Cancer Genome Atlas (TCGA) dataset, it was shown that immune activity varies substantially across tumor types (Rooney et al., 2015) . Consistent with the concept that a higher mutational load increases tumor immunogenicity, there was a positive correlation between adaptive immune activation gene signatures and mutational load across tumor types Immunity (Rooney et al., 2015) . Interestingly, this study also revealed that expression of genes associated with cytotoxic immune activation was elevated in tumors with mutations in PIK3CA or MET, while TP53 mutant tumors displayed low levels of these genes (Rooney et al., 2015) . Additionally, mutations in VHL and STK11 associated with reduced macrophage signatures (Rooney et al., 2015) . In another study into genotype-immunophenotype relationships, it was found that BRAF-mutated thyroid tumors were characterized by infiltration of immunosuppressive cells, while the RAS-mutated subtype contained higher T cell influx and displayed downregulation of MHC molecules, despite comparable mutational load (Charoentong et al., 2017) . Accordingly, oncogenic mutations also link with response to immunotherapy. Using human datasets to predict response to anti-CTLA-4 therapy in melanoma patients, it was demonstrated that mutations in oncogenes such as KRAS, ATM, and mTOR correlated with good immunotherapy response for some tumor types (Ock et al., 2017 ). These studies demonstrate that NGS studies can reveal relationships between cancer-associated genes, activation of immune cells and response to immunotherapies in a high-throughput and high-resolution manner. Together, these observations suggest that mutational load, tumor subtype, and aberrant expression of oncogenes and TSGs highly impact the tumor microenvironment. Interestingly, for certain tumors, the tumor driver genes, mutational load, and subtype are intrinsically linked, as for example aberrant expression of BRCA1 impairs the DNA damage repair machinery and therefore has consequences for the mutational load of a tumor. However powerful, these genotype-immunophenotype studies in human cancers leave several questions open. Due to the descriptive nature of these analyses, these studies do not yield mechanistic insights into causal relationships between tumor genetics and the immune composition. From a therapeutic perspective, it is important to assess whether a causal link between tumor genetics and immune contexture exists and to elucidate the underlying molecular mechanisms, since this would open new avenues for personalized immune intervention strategies. Of note, the above described clinical studies often rely on the analysis of a small tumor biopsy at a given time point, and therefore may overlook intratumoral heterogeneity and tumor evolution. For these reasons, mechanistic studies in relevant GEMMs that mimic the development, heterogeneity and progression of human tumors in an immune-proficient setting are key to understand how cancer cell-intrinsic properties can dictate the tumor immune landscape (Kersten et al., 2017) . In the next sections, we will discuss recent insights into these mechanisms and how these insights can be translated into personalized immune intervention strategies. Given the growing interest in the role of the immune system in tumorigenesis, we anticipate that more pathways will be uncovered in the years to come.
NF-kB and p53: Central Nodes in Cancer Cell-Mediated Changes in the Inflammatory Microenvironment
The mechanisms by which oncogenes and TSGs orchestrate the inflammatory tumor microenvironment are now being uncovered. Specific cancer-associated genes, besides driving cancer cell-intrinsic programs, also change the secretome of cancer cells and thereby change the immune microenvironment ( Figure 1 , Table 2 ). One notable example is NF-kB, a transcription factor that controls cell survival and proliferation, but also production of inflammatory cytokines. For example, NF-kB signaling promoted tumor development in the Kras LSL-G12D/+ ; Trp53 F/F lung adenocarcinoma model (Meylan et al., 2009 ). Interestingly, NF-kB activity was increased upon loss of p53, and restoration of p53 expression reduced its activity. Cancer cellintrinsic NF-kB inactivation resulted in increased intratumoral immune cell influx and impaired lung cancer formation in Kras ;Trp53 F/F mice (Meylan et al., 2009) , showing a link between loss of p53, NF-kB pathway activation, and an inflammatory tumor microenvironment. As one of the most frequently mutated genes in cancer (Kastenhuber and Lowe, 2017) , the tumor suppressor p53 can potentially regulate the immune infiltrate in a wide variety of tumor types, through its interactions with NF-kB or otherwise. Indeed, the control of the pro-inflammatory NF-kB pathway by p53 appears to be occurring across cancer types (Cooks et al., 2014) . For example, in the Pgrcre;Cdh1 F/F ;Trp53 F/F mouse model for endometrial cancer, the combined loss of E-cadherin and p53 resulted in increased NF-kB activity, which correlated with elevated cytokine expression and increased influx of macrophages, as compared to deletion of either gene alone (Stodden et al., 2015) . However, in another mouse model in which endometrial tumorigenesis is driven by loss of PTEN, loss of p53 did not alter neutrophil influx into early lesions (Blaisdell et al., 2015) , suggesting that this effect might be context dependent. Together, these and other studies show that NF-kB, key regulator of immune signaling in the tumor microenvironment, is controlled by p53. In several tumor models, loss of p53 activates the NF-kB pathway, stimulates the production of cytokines and other pro-inflammatory mediators from cancer cells, which through paracrine interactions modify the immune contexture. Studies in mouse models in which chemical-induced inflammation drives malignant conversion and progression show that the NF-kB-mediated inflammatory response can also be a driving force of tumorigenesis in p53-knockout models. For example, azoxymethane (AOM)-induced colonic tumorigenesis was enhanced in Villin-cre;Trp53 F/F mice that harbor p53 deletion in intestinal epithelial cells, as compared to mice with p53 proficient intestinal epithelial cells (Schwitalla et al., 2013) . Mechanistic studies in these mice revealed that loss of p53 impaired the removal of pre-neoplastic transformed cells and induced NFkB-dependent cytokine production, thus driving an inflammatory tumor microenvironment (Schwitalla et al., 2013) . Importantly, genetic ablation of IKKb, a protein involved in NF-kB activation, in cancer cells or myeloid cells, reduced tumor proliferation and invasion, demonstrating that NF-kB signaling in p53 null cancer cells or in surrounding myeloid cells plays a fundamental role in tumor progression (Schwitalla et al., 2013) . A critical feature of p53 biology in cancer not addressed in these studies is its wide variety of both activating and inactivating mutations, leading to very diverse and sometimes even opposing functions (Muller and Vousden, 2014) . How one of these p53 mutations affects NF-kB activation, was addressed in a gain-of-function (GOF) mutant p53 G515A mouse model that was repeatedly exposed to dextran sodium sulfate (DSS) to stimulate colitis-induced colorectal cancer (CRC) (Cooks et al., 2013) . Repair of DSS-induced damaged tissue was impaired in p53 G515A mice. Combined with enhanced NF-kB activity and extended inflammation, this led to an increase in colorectal tumor incidence in mice (Cooks et al., 2013) . In addition, p53 G515A mutant intestinal organoids derived from these mice showed increased tumor necrosis factor alpha (TNF-a) and CXCL1 production when compared to p53 -/-cells, which could be reverted by NF-kB knockdown (Cooks et al., 2013) . In line with these experimental findings, expression of mutant TP53 correlated with NF-kB expression in human CRC patients (Cooks et al., 2013) . These findings show that this GOF mutant p53 induces aberrant NF-kB interactions, leading to different inflammatory phenotypes than observed after loss of p53. In a mouse model for pancreatic cancer, p53 R172H has been reported to elicit similar immune phenotypes as loss of p53. , 2016) . These findings indicate that different mutations of p53 can shape the tumor microenvironment in a distinct manner. In future studies, it would be interesting to systematically dissect the differences between gain-and loss-offunction p53 mutations on NF-kB interactions and the immune landscape of the tumor. Altogether, these studies demonstrate the profound role of p53-mediated regulation of key immune signaling pathways such as NF-kB and STAT signaling, and its downstream effects on the tumor immune landscape.
MYC: A Key Controller of the Immune Microenvironment
The MYC oncogene is one of the most frequently amplified oncogenes in several tumor types, such as lymphoma, breast cancer, and NSCLC (Beroukhim et al., 2010) . As a transcription factor, (Cooks et al., 2013; Schwitalla et al., 2013) . In addition, by activating ROS, mutant p53 can induce JAK-STAT signaling and thereby increase macrophage, neutrophil, and CD4 + T cell frequencies in the tumor, while concurrently reducing CD8 + T cell levels (Wö rmann et al., 2016). (B) Mutant KRAS can increase GM-CSF by cancer cells and thereby promote neutrophil recruitment to the tumor (Pylayeva-Gupta et al., 2012) . (C) Activated Notch signaling can signal to monocytes and macrophages by driving CCL2 and IL-1b expression. Notch also drives TGF-b receptor and uPA expression, of which the latter is involved in activating macrophage-derived TGF-b, thus inducing a growth promoting signaling loop (Shen et al., 2017) . Notch can also limit the anti-tumor immune response by inhibiting C/EBPb and thereby limiting expression of IL-1, IL-6, and IL-8 (Hoare et al., 2016) . (D) Loss of tumor suppressor gene LKB1 can drive production of G-CSF, CXCL7, and IL-6 by the tumor, which promotes neutrophil recruitment, which can block anti-tumoral cytotoxic T cells (Koyama et al., 2016) . (E) ZBTB7a blocks CXCL5 production by binding its promoter, and loss of ZBTB7a therefore can lead to CXCL5-mediated neutrophils recruitment (Bezzi et al., 2018) . (F) High mutational load in tumors can increase the number of neo-antigens and thus potentially increase neo-antigen-specific T cell responses. (G) PTEN can negatively regulate NF-kB signaling. Therefore, loss of PTEN increases NF-kB-mediated expression of cytokines and growth factors that drive macrophage, neutrophil, and Treg accumulation in the tumor (Ying et al., 2011) . (H) MYC can regulate macrophage recruitment, which is promoted by p53 loss (Yetil et al., 2015) . Additionally, by inducing CCL5 and IL-1b, MYC can promote mast cell recruitment and activation (Shchors et al., 2006; Soucek et al., 2007) . MYC can also induce CCL9 and IL-23 expression, the former of which induces macrophage recruitment, while the latter limits NK, T, and B cell accumulation in the tumor (Kortlever et al., 2017) . MYC can also inhibit CD4 + T cells and macrophages by regulating PD-L1 and CD47 expression on tumor cells (Casey et al., 2016) . Lastly, the anti-tumor NK-and CD8 + T cell-response to MYC amplified tumors can be counteracted by additional loss of p53 in the tumor, while amplification of Bcl-2 promotes anti-tumor immunity (Schuster et al., 2011) . (I) SMAD4 can suppress YAP1 signaling, and loss of SMAD4 in tumors therefore drives YAP1-mediated CXCL5 production, which recruits immunosuppressive neutrophils . (J) PRKCI amplification can also induce YAP signaling. Activation of YAP1 here induces TNFa-mediated recruitment and activation of immunosuppressive neutrophils (Sarkar et al., 2017) . (K) Activated Wnt signaling via b-catenin can limit the priming of CD8 + T cells by suppression of CCL4 production, which would otherwise activate CD103 + DCs (Spranger et al., 2015) . MYC regulates many essential processes in the cell. In addition, recent studies revealed that it also has a strong hold on the tumor immune landscape ( Figure 1 , Table 2 ). Using the RIP1-Tag2;TRE-Omomyc;CMV-rtTA pancreatic b-cell cancer mouse model, in which treatment with doxycyclin induces expression of a dominant-negative MYC mutant, it was shown that inhibition of endogenous MYC in established islet tumors resulted in tumor regression, which was accompanied by a marked decrease in infiltrating macrophages and neutrophils (Sodir et al., 2011) . This study illustrates that although MYC is not an oncogenic driver in this tumor model, its endogenous expression is crucial for tumor progression and has a profound effect on the inflammatory microenvironment. In another transgenic b-cell cancer mouse model carrying a switchable form of the MYC oncoprotein in the pancreas, forced expression of MYC in b-cells resulted in pancreatic cancer formation (Shchors et al., 2006) . Importantly, Myc activation stimulated production of the potent pro-inflammatory cytokines CCL5 and interleukin-1b (IL-1b) by b cells, which facilitated tumor angiogenesis and recruitment of protumoral mast cells to the tumor (Shchors et al., 2006; Soucek et al., 2007 ). These studies demonstrate that MYC can drive tumor progression at least in part through orchestrating protumoral inflammatory conditions. The effects of MYC signaling on the tumor microenvironment may not be limited to pancreatic cancer alone. In the Em-tTA-TRE-Myc mouse lymphoma model, inactivation of MYC in established tumors resulted in a marked decrease in intratumoral macrophages (Yetil et al., 2015) . It would be of interest to assess whether the same MYC-controlled inflammatory mediators are involved in lymphoma and pancreatic cancer. Interestingly, upon additional loss of p19ARF, but not p53, MYC-dependent regulation of macrophage recruitment is not observed (Yetil et al., 2015) , suggesting that the ability of MYC to control recruitment of immune cells to tumors can be counteracted by other aberrantly expressed genes. This is also illustrated by the observation that the spontaneous anti-tumor T and NK cell response in the Em-MYC lymphoma model could only be elicited when Bcl-2 was overexpressed, but not when p53 was deleted (Schuster et al., 2011) . How p53 loss counteracts MYC activity in modulating the tumor microenvironment however remains a subject of future research.
MYC can also control the immune landscape of tumors by regulating expression of immune checkpoint molecules. In the Em-tTA/tet-O-MYC lymphoma model and cell lines with switchable MYC expression, MYC increased the expression of both PD-L1 and the ''don't eat me'' receptor CD47 on cancer cells by binding directly to their respective promoters (Casey et al., 2016) . Exogenous overexpression of PD-L1 and CD47 on cancer cells limited the CD4 + T cell and macrophage recruitment to the tumor. Moreover, MYC inactivation downregulated CD47 and PD-L1 expression and induced tumor regression, while exogenous overexpression of PD-L1 and CD47 in cancer cells enhanced disease progression (Casey et al., 2016) . Although not experimentally proven, this study suggests that MYC may facilitate tumor immune escape by induction of immune checkpoints. Similarly, a MYC amplification-dependent T cell-poor environment has also been reported in human neuroblastomas, but in these tumors genomic amplification of N-MYC inversely correlated with PD-L1 expression, possibly due to MYC-induced suppression of interferons and pro-inflammatory signaling pathways (Layer et al., 2017) . These studies show that MYC activation in tumors can control immune checkpoint molecules and T cell influx, but the underlying mechanisms may differ between tumor types. Another mechanism by which MYC regulates the immune phenotype of tumors was recently demonstrated in the Kras G12D -driven lung adenocarcinoma model. Here, conditional MYC amplification resulted in a rapid decrease of intratumoral B, T, and NK cells, and an increase in macrophages (Kortlever et al., 2017) . Mechanistically, MYC amplification led to increased expression of IL-23 by cancer cells, which inhibited B, T, and NK cell recruitment, and increased expression of CCL9, which recruited and activated macrophages in the tumor. These macrophages inhibited T cells, while also promoting angiogenesis. Interestingly, these tumors rapidly acquired dependency on MYC amplification, and MYC de-activation resulted in tumor regression in an NK cell-dependent fashion (Kortlever et al., 2017) . These findings suggest that targeting MYC in tumors would be an attractive therapeutic strategy to unleash anti-tumor immunity. While MYC is as of yet not directly targetable, indirect therapeutic strategies emerge. One such strategy targets the epigenetic modulators DNA methyl transferases (DNMTs) and histone deacetylases (HDACs). Combined treatment of NSCLC mouse models with DNMT and HDAC inhibitors reduced MYC expression, increased CCL5 levels, decreased macrophage influx, and increased cytotoxic T cell influx and inhibited tumor growth (Topper et al., 2017) . This study demonstrates that indirect targeting of MYC might prove therapeutically beneficial by limiting tumor growth and reversing immune evasion. However, this study did not formally exclude a direct effect of the epigenetic modulators on the immune system. These studies show that in addition to the key role MYC has in tumor cell-intrinsic processes, this transcription factor can exert a wide variety of functions to modulate both the innate and the adaptive immune landscape of several tumor types. While MYC is not directly targetable, insights into these mechanisms open up new ways to target MYC-regulated signaling.
Other Genetic Determinants of the Tumor Immune Landscape
The effect of oncogenes and TSGs on the tumor immune landscape is not just limited to the abovementioned genes and pathways; several other genetic events and downstream immune effects have been described (Figure 1, Table 2 ). One example is the impact of the Ras oncogene on tumor-associated myeloid cells. Mutated Ras strongly induces expression of IL-6 and IL-8 in in vitro models (Ancrile et al., 2007; Sparmann and Bar-Sagi, 2004) . These Ras-controlled cytokines have been reported to facilitate myeloid cell infiltration and tumor progression (Ancrile et al., 2007; Sparmann and Bar-Sagi, 2004 ;Pten +/F mouse models for pancreatic cancer, it was demonstrated that loss of Pten resulted in increased activation of the NF-kB pathway, driving expression of several immune regulators by cancer cells, such as G-CSF, IL-23 and CXCL1 (Ying et al., 2011) . Pten loss and the downstream NF-kB activation not only accelerated tumor progression, but also influenced the frequency of intratumoral neutrophils, monocytes, and Tregs (Ying et al., 2011) . Another study showed a profound role for the STK11/LKB1 tumor suppressor in NSCLC. Comparing Kras G12D/+ with Kras G12D/+ ;Lbk1 À/À mice, it was found that loss of Lkb1 resulted in increased IL-6 production, which resulted in higher intratumoral and systemic immunosuppressive neutrophil levels (Koyama et al., 2016) . Indeed, blockade of IL-6 resulted in increased levels cytotoxic CD8 + T cells and tumor control (Koyama et al., 2016) . Although not all of these studies elucidated the functional consequence of the altered immune landscape on tumor growth, they demonstrate that a wide variety of cancer-driving mutations can dictate the composition of the tumor microenvironment. Collectively, studies pertaining to cancer cell-intrinsic pathways and immune contexture are gaining ground and have identified various cancer-driving genes that orchestrate diverse immune landscapes in the tumor. Thus far, many of these studies have been relatively biased and focused on a single genetic pathway in a single mouse tumor model. A more systematic assessment of immune cell populations in relation to tumor genotypes was recently performed in two studies. One compared four independent lung cancer GEMMs: Ccsp-rtTA; TetO (Busch et al., 2016) . This approach revealed key differences in immune cell content between the different tumor genotypes, such as that Egfr
L858R
-driven tumors showed lower frequencies and activation of CD8 + T cells compared to Kras-driven tumors, whereas NK cells in Krasdriven tumors, but not EGFR mutants, show downregulation of activation markers (Busch et al., 2016 (Bezzi et al., 2018) . Mechanistic studies revealed distinct chemokine production by tumors controlled by loss of Zbtb7a, p53, or Pml and blockade of the respective signaling pathways impaired innate immune cell recruitment and tumor progression. These studies demonstrate the powerful potential of GEMMs in identifying the complex mechanisms that control the tumor microenvironment and potential for immunomodulatory therapeutic intervention based on genetic aberrations in the tumor. With the rapid developments in mouse model-generating techniques (Huijbers, 2017) , future systematic approaches in GEMMs may increasingly reveal causal genotype-immunophenotype relationships, and its impact on tumor progression.
The Role of Oncogene-Induced Senescence in Promoting an Inflammatory Tumor Microenvironment A cancer-cell-intrinsic pathway in which many of the abovementioned cancer-driving genes are involved and that strongly influences the intratumoral immune landscape is cellular senescence. In a process called oncogene-induced senescence (OIS), precancerous cells undergo cell-cycle arrest upon activation of oncogenic signaling. Cellular senescence is a physiological program that can be activated in response to cellular stress and aging, leading to an essentially irreversible cell proliferation arrest ;TRE.shp53 inoculation model for liver cancer (Xue et al., 2007) . Activation of p53 did not lead to tumor cell death in a cell-autonomous manner, but rather neutrophils, macrophages and NK cells were recruited to these tumors by activated SASP and removed the senescent cells (Xue et al., 2007) . Indeed, maintenance of WT p53 was a prerequisite of senescence induction, as also observed in other tumor models (Cooks et al., 2013; Pribluda et al., 2013) . Because NF-kB is a key transcription factor in SASP activation (Chien et al., 2011) , the regulation of NF-kB by the p53 pathway might play an important role in SASP regulation. In colorectal tumor models, Wnt signaling can also regulate SASP induction. VillincreER T2 ;CKIa F/F mice, which display hyper-activated Wnt signaling due to loss of CKIa, exhibit growth arrest of colorectal tumors and induction of senescence, paired with an inflammatory response (Pribluda et al., 2013) . SASP is maintained upon additional p53 deletion in this model, however, it dissociates from growth arrest while the inflammatory response continues, resulting in inflammation-accelerated tumorigenesis (Pribluda et al., 2013) . These findings illustrate that depending on the genetic makeup of cancer cells, the senescence-associated inflammatory response can result in two opposing outcomes: tumor inhibition or tumor promotion. In addition to p53 and Wnt, mTOR signaling was shown to induce SASP in CRC and prostate cancer cells in vitro (Laberge et al., 2015) . mTOR inhibition by rapamycin decreased mTOR-induced SASP and decreased influx of macrophages, T, B, and NK cells into inoculated Nras Immunity Review that targeted therapies, such as rapamycin, may reduce tumorinduced inflammation, but potentially also reduce senescent tumor cell clearance by infiltrating immune cells, thus demonstrating the complexity of targeting SASP. Nonetheless, these studies reveal the essential role of oncogenes and TSGs in SASP induction and the potential of targeting these genes to revert tumor-promoting SASP. The composition of SASP mediators secreted by senescence cells is dynamic and experimental evidence points toward NOTCH1 as one of the master regulators controlling this SASP diversity. In Nras G12V mutant tumor models, Nras
G12V
-induced senescence was accompanied by fluctuations in endogenous Notch expression levels (Hoare et al., 2016) . Ectopic expression of active Notch in an Nras G12V -dependent oncogene-induced senescence liver model increased cancer progression in a non-cell-autonomous fashion (Hoare et al., 2016) . In this model, Notch levels determined the composition of the SASP and subsequent immune function. Notch inhibited lymphocyte-mediated clearance of senescent cells through repression of C/EBPb. Reversely, inhibition of Notch during senescence led to an increase of lymphocyte-mediated senescent cell clearance (Hoare et al., 2016) . This Notch-dependent cytokine production and shaping of the immune phenotype of tumors was also demonstrated in breast cancer, where tumor-intrinsic Notch signaling increased monocyte and macrophage accumulation by increasing expression of IL-1b and CCL2 (Shen et al., 2017 ). These studies demonstrate that immune cell influx can be strongly influenced by SASP, but also that the activity of cancer cellintrinsic genes play important roles in determining the spectrum of inflammatory mediators produced within the tumor. Indeed, in the Ptf1a-cre;Kras LSL-G12D/+ mouse model for pancreatic cancer, genetic deletion of RelA, the gene that encodes the NF-kB subunit p65, abrogated senescence and SASP, thus enhancing progression of pancreatic tumors (Lesina et al., 2016) . While reducing SASP, RelA deletion led to a marked increase in immunosuppressive cells and decreased T cell activation in the pancreata of these mice (Lesina et al., 2016) . Therefore, in these tumors, the cancer-immune cell crosstalk is not limited to SASP.
The infiltrating immune cells can also impact senescence itself. In Pten-induced senescent prostate tumors, CD11b
+ Gr-1 + cells can actively counteract SASP by producing IL-1 receptor antagonist . Additionally, senescence programs in tumor-associated stromal cells also impact tumorigenesis through modulation of immune responses. In a carbon tetrachloride (CCl 4 )-induced liver fibrosis model, p53 activity in hepatic stellate cells (HSCs) limits fibrosis and cirrhosis, and reduced liver tumorigenesis in mice treated with CCl 4 and diethylnitrosamine (DEN) (Lujambio et al., 2013) . Here, wildtype p53 cooperated with NF-kB to induce senescence and SASP in HSCs, which induced a tumor-inhibiting phenotype in macrophages. Loss of p53 in stromal HSCs changed their secretome, induced the polarization of macrophages toward a tumorpromoting phenotype and accelerated inflammation-induced hepatocellular carcinoma (Lujambio et al., 2013) , indicating that also stromal cell-intrinsic p53 controls tumorigenesis via modulation of the immune system. Collectively, depending on the tumor type and oncogenic wiring, the activated SASP-related genes and downstream inflammatory profile may differ, resulting in a wide spectrum of immune responses that range from tumor-promoting chronic inflammatory responses to immune-mediated clearance of cancer cells (Figure 2 ). Deeper mechanistic insights into the causal relationship between genetic events in cancer cells and the dynamic aspects of SASP may open new avenues for therapeutic intervention. Indeed, this is exemplified by a study showing that the efficacy of docetaxel could be enhanced by pharmacologically targeting Pten-loss-induced SASP in a transgenic prostate tumor model . Important to note however, is that senescent cells are not the only cells actively secreting inflammatory mediators in the tumor, and the cytokine milieu and its net effect on the immune landscape is not only determined by SASP. Therefore, it is of key importance to delineate how the tumor-promoting aspects of SASP can be reverted, while enhancing the tumor-limiting aspects.
Mechanisms of Cancer-Cell-Intrinsic Regulation of Parameters of the Cancer Immunity Cycle and Immune Checkpoint Blockade Response As discussed above, the mutational load of tumors is one of the determinants linked with responsiveness to immune checkpoint inhibition. The expectation is that many other parameters, including the activation of certain oncogenes or inactivation of TSGs, are associated with therapeutic benefit as well, and that they may differ per tumor (sub)type. As of yet, preclinical studies focused on unlocking the relationship between tumor genetics and response to immunotherapy are still relatively limited, however, the concept is emerging that genetic events in cancer cells dictate various aspects of the tumor-immunity cycle (Chen and Mellman, 2013) , such as activation of immunosuppressive myeloid cells, induction of immune checkpoint molecule expression, regulation of DC activation and T cell priming, and induction of tumor resistance to T cell attack.
One such genetic event is mutation in the serine/threonineprotein kinase ATR. ATR is a DNA damage sensor and is frequently mutated in melanoma. It has been reported to influence important parameters of immunotherapy response, such as intratumoral T cell influx and expression of immune checkpoints. Transgenic expression of an ATR LOF mutant in the Tyr::CreERT2; Braf
V600E
;Pten F/F model for melanoma diminished T cell influx in the tumor, while increasing B cells and macrophages . This was associated with an increase in expression of Arginase 1, CD206, and PD-L1 in the tumor, suggesting a more T cell suppressed environment. Cyclindependent kinases (CDKs)-essential regulators of the cell cycle-have also been shown to be involved in immune checkpoint regulation. In medulloblastoma (MB) cell line inoculation models, the anti-tumor function of CD4 + T cells depends on disruption of CDK5 in MB cells (Dorand et al., 2016) . In this model, CDK5 is required for PD-L1 expression by MB cells, as CDK5 is a repressor of IRF2 and IRF2BP2, that both regulate IFN-g-mediated PD-L1 expression (Dorand et al., 2016) . Additionally, it was recently shown that the activating Ras G12V mutation can cause stabilization of PD-L1 mRNA via activation of MEK (Coelho et al., 2017) . However, the functional relevance of these changes for immunotherapy and disease progression in relation to ATR, CDK5, and RAS remains unaddressed in these studies.
Another mechanism by which tumor cells may regulate immunotherapy response is via establishment of an immunosuppressive microenvironment. Overexpression of PRCKI, a protein kinase, is frequently observed in a variety of cancer types, including high-grade serous ovarian carcinoma (Sarkar et al., 2017) . Upon conditional overexpression of PRKCI in the Pax8-rtta; Trp53 F/F ;Pten F/F mouse model for ovarian cancer, tumors upregulated TNF-a, as a result of which tumors were strongly infiltrated by immunosuppressive neutrophils, thus decreasing CD8 + T cell influx (Sarkar et al., 2017) . This TNF-amediated neutrophil recruitment was dependent on PRKCIinduced YAP1-a key transcriptional regulator and oncogene-signaling in cancer cells (Sarkar et al., 2017 prostate cancer mouse models, a strong YAP1-dependent influx of neutrophils was observed upon cancer cell-intrinsic Smad4 loss . Here, Smad4 loss caused YAP1-mediated upregulation of CXCL5 in tumor cells. This in turn recruited CXCR2 + neutrophils, which suppressed the CD8 + T cell response to the tumor . These studies show that Smad4 and PRCKI both function as inducers of immunosuppression via cancer cell-intrinsic YAP signaling and that YAP inhibitors-which are currently in preclinical development-may prove beneficial to alleviate T cell suppression. Collectively, these studies show that oncogenic pathway activation can significantly impact on parameters of the cancer-immunity cycle. However, the functional consequences of these genetic changes on immunotherapy response have not been addressed in these studies. Focal Adhesion Kinase (FAK) activity in cancer cells has also been identified as an important regulator of immunosuppression in the tumor microenvironment, and its impact on immunotherapy efficacy has been addressed experimentally. FAK amplification was observed in the p48-Cre;Kras LSL-G12D ;
Trp53 F/+ model for PDAC, and therapeutic targeting of FAK improved survival by alleviating the immunosuppressive microenvironment, mainly by reducing macrophages, monocytes, and neutrophils in the tumor . This held true for cancer-cell-specific ablation of FAK, indicating that immune cell changes occur via FAK targeting in cancer cells. Importantly, inhibition of FAK synergized with anti-CTLA-4/anti-PD-1 combination immunotherapy , indicating that interference with this cancer cell-intrinsic signaling pathway renders tumors sensitive to immunotherapy.
DC activation and T cell priming can also be influenced by cancer cell-intrinsic signaling pathways. Using the Braf priming and intratumoral accumulation of T cells (Spranger et al., 2015) . As a consequence, b-catenin-active tumors failed to respond to anti-CTLA-4/anti-PD-1 treatment. In line with these data, active WNT/b-catenin signaling in human metastatic melanomas correlated with absence of a T cell gene expression signature (Spranger et al., 2015) . This study highlights the importance of cancer cell-intrinsic WNT/b-catenin signaling in immune evasion of tumors, and suggests that targeting the WNT pathway may improve the therapeutic benefit of immune checkpoint inhibition in tumors with active b-catenin signaling. Some oncogenes and TSGs have been demonstrated to regulate immune checkpoint molecule expression in a cell-autonomous fashion, and thus influence response to immunotherapy. In EGFR-driven lung cancer mouse models, EGFR mutation caused rapid induction of an immunosuppressive tumor microenvironment (Akbay et al., 2013) . The EGFR mutant lung tumors displayed increased expression of immune checkpoint molecules such as PD-1 and PD-L1, which led to an increased sensitivity to anti-PD-1 monotherapy in these tumor-bearing mice. In line with these pre-clinical findings, EGFR pathway activating mutations in human lung tumors, and not the other prevalent driver mutation KRAS G12V , correlated with PD-L1 expression (Akbay et al., 2013) . Intriguingly, another study reported KRAS mutant lung tumors in patients treated with anti-PD-1 to have higher PD-L1 levels relative to EGFR mutated tumors (Garon et al., 2015) , potentially mediated by KRAS-induced stabilization of PD-L1 (Coelho et al., 2017) . The different levels of PD-L1 regulation by mutated oncogenes and the underlying mechanisms will therefore be an important topic of future research. Similarly, PTEN status is implicated in immunotherapy response due to its ability to render cancer cells resistant to T cell attack. In a cohort of melanoma patients, PTEN loss correlated with low TIL influx and poor response to anti-PD-1 therapy (Peng et al., 2016) . Using xenograft mouse models for melanoma, it was shown that PTEN loss in cancer cells reduced T cell influx, and resulted in reduced autophagy, leading to resistance to T cell-mediated killing (Peng et al., 2016) . Treating PTEN null tumors with a PI3Kb inhibitor, thus reducing the dysregulated AKT activity in these tumors, improved response to anti-PD-1 therapy, highlighting a potential therapeutic approach for PTEN null melanoma in controlling resistance to anti-PD-1 therapy.
Altogether, these studies show that aberrant signaling pathways in cancer cells can impact the anti-cancer immune response and the response to immune checkpoint inhibition (Figure 3) . One aspect that needs to be taken into account when using GEMMs to model human cancers with high mutational load, is that the mutational load in transgenic mice may not correspond to that of the human tumors, due to the strong driver mutations engineered in these mice. This could be overcome by for example exposing early melanoma lesions to UV irradiation, or early lung lesions to carcinogens. The drawback however, is that this may not result in clonal antigens and the mutational spectrum may be highly variable from one mouse to the next. Alternatively, transgenic models that are prone to generate high mutational load tumors can be used, such as those with mutations in DNA repair machinery, or mutations can be engineered in a tissue-specific manner. This would allow for physiological modeling and therefore correct assessment of pre-clinical immunotherapeutic strategies in an immunocompetent setting.
Targeting Genetic Pathways to Unleash Anti-Tumor Immunity One major theme that emerges from the aforementioned studies is that many targeted therapies, specific for hyperactive signaling pathways, are likely to also exert a major impact on the immune contexture of tumors. Most targeted drugs initially induce very strong anti-cancer effects in patients, however, the rate of durable clinical responses is disappointingly low (Groenendijk and Bernards, 2014) . Given the previously unrecognized impact of these targeted drugs on the immune landscape of tumors, the question arises whether we can rationally induce a favorable immune environment in tumors or even sensitize tumors to immunomodulatory drugs by selective usage of targeted therapy. In this regard, we can learn from the growing number of pre-clinical studies that have addressed the impact of targeted drugs on the immune microenvironment of tumors and their response to immunotherapy. For example, as described above, + T cell levels, while decreasing Tregs in the tumor. Combined with anti-PD-L1 treatment, this leads to a marked tumor regression (Goel et al., 2017) . (B) In EGFR mutant lung cancer, PD-L1 has been described to be upregulated, increasing the sensitivity to anti-PD-L1 therapy (Akbay et al., 2013) . KRAS mutation in lung cancer can also drive PD-L1 expression, to a higher extent than EGFR mutation (Garon et al., 2015) . In MYC-driven lung tumors, combined inhibitors against HDAC and DNMT both target MYC and CD8 + T cells, thus limiting tumor growth (Topper et al., 2017) . (C) Pancreatic tumors with FAK amplification show an accumulation of immunosuppressive cells in the tumor. FAK1/2 inhibitors alleviate this, and combined with anti-PD-1 and anti-CTLA-4 treatment limit tumor progression . Pancreatic tumors with p53 loss or mutation establish an immunosuppressive microenvironment by JAK-STAT signaling. Targeting JAK2 in combination with gemcitabine reduces tumor burden . (D) In melanoma, ATR loss-of-function mutation increases PD-L1 and thereby potentially sensitizes these tumors to anti-PD-L1 treatment. In PTEN null melanomas, the resulting activated AKT signaling can be reduced by PI3Kb inhibitors, which in combination with anti-PD-1 limits tumor growth (Peng et al., 2016) . Combining MEK and BRAF inhibitors in BRAF V600E mutant melanoma also synergize with anti-PD-1 treatment (Hu-Lieskovan et al., 2015) . (E) In prostate tumors with loss of SMAD4, YAP1-mediated immunosuppressive neutrophil recruitment can be counteracted by YAP1 inhibitors or anti-CXCR2 treatment .
BRAF mutant thyroid tumors are characterized by infiltration of immunosuppressive cells (Charoentong et al., 2017) , raising the question of whether inhibition of mutant BRAF in thyroid cancer would induce a more favorable immune contexture. Indeed, combined targeting of BRAF V600E and SRC increased influx of CD8 + T cells, B cells, and macrophages and reduced tumor growth in an orthotopic inoculation model for anaplastic thyroid cancer (Vanden Borre et al., 2014) . Also in patients with BRAF V600E mutated metastatic melanoma, BRAF inhibition with vemurafenib enhanced melanoma antigen presentation by cancer cells, increased cytotoxic T cell influx, and decreased immunosuppression (Frederick et al., 2013) . This is in line with findings in BRAF V600E melanoma mouse models in which BRAF inhibition improved adoptive T cell therapy (Koya et al., 2012) and BRAF inhibition combined with MEK inhibition synergized with anti-PD-1 treatment (Hu-Lieskovan et al., 2015) . These studies indicate that therapeutic targeting of cancer cell-intrinsic oncogenic driver mutations can be exploited to induce a favorable immune environment and thus sensitize tumors to cancer immunotherapy.
Other targeted therapies have also been reported to exert strong effects on the cancer-immune cell crosstalk. For example, CDK4/6 inhibitors were originally designed to selectively inhibit cell-cycle progression, but emerging experimental evidence reveals that part of the therapeutic benefit of these inhibitors lies in their anti-tumor immunity promoting capacity. In the MMTV-rtTA/tetO-HER2 mouse model for breast cancer, treatment with the CDK4/6 inhibitor abemaciclib leads to tumor regression by inducing anti-tumor immunity (Goel et al., 2017) . In vitro studies revealed that CDK4/6 inhibition increased antigen presentation and production of type III interferons by cancer cells, which induced CD8 + T cell proliferation and activation (Goel et al., 2017) . Simultaneously, CDK4/6 inhibition reduced systemic and intra-tumoral regulatory T cell numbers, which occurred independent of the presence of a tumor. Both the effect of the CDK4/6 inhibitor on antigen presentation by cancer cells and the impact on regulatory T cells was dependent on inhibition of the RB-E2F-DNMT1 axis (Goel et al., 2017) . Importantly, by modulating the immune microenvironment, anti-CDK4/6 treatment improved response to anti-PDL1 in MMTV-rtTA/tetO-HER2 mice (Goel et al., 2017) . Also, in an in vitro small molecule screen, CDK4/6 inhibitors were identified to directly enhance T cell activity. Mechanistically, CDK4/6 inhibition resulted in de-repression of NFAT activity in T cells, resulting in increased T cell accumulation in lung tumors of Kras LSL-G12D ;Trp53 F/F mice, which synergized with immune checkpoint inhibition (Deng et al., 2018) . These two studies illustrate that CDK4/6 inhibitors, which were originally developed to induce cell-cycle arrest in cancer cells, work in part by counteracting tumor immune evasion. This is a result of combined targeting of cancer cell-intrinsic pathways, changing parameters of the cancer-immunity cycle, and direct targeting of T cells. Targeted therapies have also been reported to affect the abundance and function of myeloid cells in tumor-bearing hosts, since the signaling pathways targeted by these drugs also play functional roles in the immune system (Muñ oz-Fontela et al., 2016) . For example, neutrophils in the Hgf-Cdk4 R24C model for melanoma and cell line inoculation models impair the anti-tumor CD8 + T cell response (Glodde et al., 2017) . In this study, cMET inhibition enhanced the efficacy of adoptive cell transfer and immune checkpoint therapies by direct targeting of immunosuppressive neutrophils that express the cMET receptor (Glodde et al., 2017) . However, targeting cMET-expressing neutrophils in another study promotes tumor progression (Finisguerra et al., 2015) , highlighting the complex model-dependent and dual role of neutrophils in cancer biology (Coffelt et al., 2016) . Likewise, it has been reported that the depletion of immunosuppressive CD11b + Gr1 + cells as a bystander effect of other targeted therapies, for example by ITK/BTK-inhibitor ibrutinib, benefits the response to immunotherapies in cell line inoculation models for breast cancer and melanoma (Sagiv-Barfi et al., 2015; Stiff et al., 2016) . Ibrutinib can also reprogram macrophages, relieve immunosuppression, and facilitate CD8 + cytotoxicity in PDAC-bearing mice (Gunderson et al., 2016) . These studies highlight that targeted drugs can impact the immune contexture of tumors via their working mechanism on cancer cells, which indirectly changes the immune landscape, and via their direct effect on immune cells. Insights into the complexity of the combined effect of these targeted drugs on the cancer cells and tumor microenvironment will help us to maximize the therapeutic benefit of targeted drugs in combination with immunomodulatory strategies (Figure 3 ).
Conclusions and Future Directions
From the studies discussed in this review it has become clear that activation of oncogenes or loss of TSGs not only exert an intrinsic influence on the fate of cancer cells, but can have profound effects on tumor-host interactions. Commonly mutated genes that lie at the basis of tumorigenesis can actively participate in recruitment, activation, or dampening of the immune system. This could in part explain the heterogeneity between and within tumor types in immune infiltration and activation. From a clinical perspective, these insights will help identify patients that would or would not benefit from immunomodulation. Moreover, identifying the mechanisms underlying the causal relationship between the genetic makeup of tumors and their immune landscape may identify novel targets for anti-cancer immunomodulatory therapies. The studies presented here likely only reveal the tip of the iceberg. Most studies focus on one particular oncogene or TSG, and the majority of research is concentrated on the primary tumor. This leaves the effect on the systemic immune milieu and metastasis largely unaddressed. With increasingly sophisticated methodologies to generate mouse models that closely mimic the genetics and biology of human cancer and approaches to analyze tumors in depth, it will be possible to screen for a multitude of genetic and epigenetic alterations and their effect on the immune system. In vivo genetic manipulation will be key to delineate the spatiotemporal regulation of the tumor immune landscape, both in the primary as well as the metastatic lesion. This knowledge will help maximize the potential of immunomodulatory therapeutics for cancer patients and provide rationale for personalized combination therapies based on the genetic profile of tumors.
